Category Archives: Immunology

WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the Company or Werewolf) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the bodys immune system for the treatment of cancer, today provided a business update and reported financial results for the first quarter ended March 31, 2023.

In the first quarter, Werewolf has focused on execution by progressing our INDUKINE pipeline and enrolling ongoing first-in-human clinical trials for our lead programs, WTX-124 and WTX-330. In addition, preclinical data presented at AACR and published in Cancer Immunology Research continues to demonstrate the robustness of our PREDATOR platform showing that Werewolfs conditional activation technology results in potent anti-tumor activity alongside an improved therapeutic index, said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. Looking ahead, in the fourth quarter we plan to share initial safety, tolerability, and preliminary efficacy data from our Phase 1/1b clinical trial of WTX-124 in solid tumor types.

Finally, wed like to express our deep appreciation to Reid Leonard, Ph.D., Werewolfs Chief Operating Officer, who is retiring effective June 30, 2023, after a long and successful career in the biopharmaceutical industry. Reid is a founding member of the Werewolf Executive Team and has been instrumental in leading and advancing all aspects of organizational operations. We have benefited greatly from Reids significant expertise, and the strong team he has built and business process he has established will ensure continued operational excellence going forward. We wish Reid the very best in his retirement.

Recent Highlights and Upcoming Milestones

WTX-124:a systemically delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule being developed as monotherapy and in combination with checkpoint inhibitor therapy in multiple solid tumor types.

WTX-330:a systemically delivered, conditionally activated Interleukin-12 (IL-12) INDUKINE molecule being developed in refractory and/or immunologically unresponsive tumors.

Early-Stage Pipeline:

Financial Results for the First Quarter of 2023:

About Werewolf Therapeutics:Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit http://www.werewolftx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risk and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolfs future operations, prospects, plans, the projection of the cash runway, the expected timeline for the clinical development of product candidates and availability of data from such clinical development, and the potential activity and efficacy of product candidates in preclinical studies and clinical trials constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words aim, anticipate, believe, contemplate, continue, could, design, designed to, estimate, expect, goal, intend, may, might, objective, ongoing, plan, potential, predict, project, promise, should, target, will, or would, or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and the Companys ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; the Companys ability to obtain sufficient cash resources to fund the Companys foreseeable and unforeseeable operating expenses and capital expenditure requirements; the impact of the COVID-19 pandemic on the Companys business and operations; as well as the risks and uncertainties identified in the Risk Factors section of the Companys most recent Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Companys views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of this press release.

Investor Contact:Josh RappaportStern IR212.362.1200Josh.rappaport@sternir.com

Media Contact:Peg RusconiVERGE Scientific Communicationsprusconi@vergescientific.com

Company Contact:Ellen LubmanChief Business OfficerWerewolf Therapeuticselubman@werewolftx.com

Go here to see the original:
Werewolf Therapeutics Reports First Quarter 2023 Financial Results ... - BioSpace

Immunology

PeaceHealth cuts Bellingham jobs, announces clinic closure and reduces some services – Yahoo News

May 13, 2023 medical

PeaceHealth, a Pacific Northwest not-for-profit health-care system, is closing a Bellingham clinic and ending certain services, resulting in the elimination of 32 local jobs.

Across PeaceHealths 10 communities it serves in Washington, Oregon and Alaska, and its headquarters in Vancouver, Washington, 251 positions have been eliminated, according to an email from Beverly Mayhew, senior director of marketing and communications for PeaceHealths northwest network.

In Bellingham, the 32 terminated positions come from changes in the Allergy & Immunology Clinic, the Sleep Lab and the Outpatient Palliative Care program.

The Allergy & Immunology Clinic will close permanently, although a date has not been chosen yet, according to Mayhew. The clinic at 4545 Cordata Parkway, Suite 1C, is not accepting new patients, and current patients can continue to receive care from the clinic until further notice.

We recognize that patients will require transition plans specific to their condition, physicians and clinic staff have prioritized patient needs and identified appropriate clinical options for each type of patient. The options for asthma and allergy care locally range from continuing with another allergist or with primary care providers.

Fortunately, there is an excellent community-based allergist at the Bellingham Asthma, Allergy & Immunology Clinic, and primary care providers at PeaceHealth Medical Group and other family medicine clinics are well versed in allergy care, Mayhews statement read.

Bellinghams Sleep Lab will also stop providing overnight sleep lab services on May 15, eliminating some jobs. The lab will still provide sleep consultations and home sleep studies, and will help patients find alternatives for overnight sleep lab services.

PeaceHealth is also eliminating some caregiver roles within the Outpatient Palliative Care program in Bellingham, but will continue to offer care for patients in various ways.

We will continue to support patients with complex care needs using a new model which includes care navigators, coupled with support from our home health team and, if appropriate, our hospice caregivers. Every effort will be made to minimize the impact to patients through this transition by identifying their specific needs and aligning appropriate services, Mayhew wrote.

PeaceHealth credits the job eliminations to the costs of health care rising slower than what it was earning for the care being provided, according to Mayhew.

To make sure that we can continue to sustain our mission into the future, we conducted a comprehensive review of all services and operations. The result is growth in some areas and reductions in others.

Immunology

Help! My skin is itchy – Parkview Health

May 13, 2023 medical

This post was written by Heather Willison, NP, PPG Allergy, Asthma & Immunology.

Few things are as irritating as an itch. Weve all experienced that prickling sensation also called pruritus that demands a good scratch. We often dont consider why our skin is itchy to begin with, unless the discomfort decides to stick around for an extended period of time. There are several causes of pruritus, with some triggers being easier to pinpoint than others, and varied degrees of severity.

If you find yourself scratching, it could be attributed to one of these common sources.

Whether the source of the issue is simple or more complicated, there are solutions for this bothersome side effect.

See the original post here:
Help! My skin is itchy - Parkview Health

Immunology

Takeda reports 12.8% rise in FY2022 revenue – Pharmaceutical Technology

May 13, 2023 medical

Takeda has reported a 12.8% increase in itsreportedrevenue to $29.96bn (Y4,027bn) during the fiscal year 2022 (FY2022) compared to that reported in FY2021.

At a constant exchange rate (CER), the companys core revenue grew by 3.5% compared to the previous year.

In the FY2022 ending 31 March 2023, the company also reported a 6.4% rise in its operating profit to $3.65bn (Y490.5bn) compared to 2021.

Reported earnings per share (EPS) grew by 38.8% to $1.5bn (Y204bn) and net profit for FY2021 increased by 37.8% to $2.36bn (Y317bn).

The same fiscal year recorded a 13% decline to $7.27bn (Y977.2bn) in operating cash flow.

The company has provided commercial updates across its five key business areas: gastroenterology (GI), rare diseases, plasma-derived therapy (PDT) immunology, oncology and neuroscience.

Its GI business reported an 8.7% increase in revenue to $8.145bn (Y1,094.5bn) on a CER basis.

Entyvio, for ulcerative colitis (UC) and Crohns disease (CD), steered the growth in the revenue of this business.

Rare diseases reported revenue growth of 4.8% to $5.38bn (Y723.4bn) and PDT immunology reported growth of 15.3% to $5.048bn (Y678.4bn), both on a CER basis.

Oncology reported a 14.4% decline in reported revenue on a CER basis to $3.26bn (Y438.7bn).

In neuroscience, reported revenue rose by 12.1% to $4.75bn (Y637.7bn) on a CER basis.

Takeda chief financial officer Costa Saroukos stated: Im pleased to report that Takeda delivered or exceeded management guidance in FY2022 and booked a record core operating profit of almost Y1.2tn.

Our topline and profit performance was driven by our growth and launch products, which grew 19% at a constant exchange rate.

Strong financial discipline and free cash flow have enabled us to deleverage rapidly while investing in growth.

Continue reading here:
Takeda reports 12.8% rise in FY2022 revenue - Pharmaceutical Technology

Immunology

Welcoming a new column: Vasso’s corner – The immune system – Neos Kosmos

May 13, 2023 medical

Vasso is a renowned immunologist, with a focus on medicinal chemistry, cellular biology, and clinical research. She has developed drugs and vaccines through her translational research expertise.

Vasso has held various research positions at prestigious institutions worldwide and has been recognised with over 100 awards and honours. She has published over 500 research papers and is an inventor on 20 patents and over 90 sub-patents. Vassos work has been instrumental in developing vaccines against cancer and applying immunotherapies to multiple sclerosis, type-1 diabetes, drug addiction, Alzheimers disease, and other diseases.

Her research also focuses on understanding mechanisms and developing interventions for mental health issues, chronic diseases, infectious diseases, autoimmunity, and ageing. Immunology is essential in maintaining a healthy immune system and Vasso applies her expertise in immunology to tackle various diseases.

The Immune System

The immune system is part of our blood system those being the white blood cells within blood. These are the cells which are the first line of defence, and constantly come in contact with anything that enters our body; bacteria, viruses, dust, basically anything foreign. They get rid of these foreign substances without even realising.

However, some invaders remain and cause damaging effects, such as bacteria and viruses which result in various infections. The body usually eliminates these invaders within days to a few weeks.

The immune system is responsible for keeping the body in a happy and healthy state. However, if the immune system gets over activated, cytokine storm can occur, inflammation occurs, autoimmune diseases can occur etc. Maintaining a healthy immune system is important to keep well and age healthy.

Diet, regular physical activity, sleep, social activities, sunlight, and relaxation all contribute to keeping an immune system healthy.

Over the next few months, I will be describing various diseases and the role the immune system plays in each of these diseases, and relaxation all contribute to keeping an immune system healthy.

View post:
Welcoming a new column: Vasso's corner - The immune system - Neos Kosmos

Immunology

UC statement on Gov. Newsom’s 2023-24 revised budget proposal – University of California

May 13, 2023 medical

University of California President Michael V. Drake, M.D., today (May 12) issued the following statement on Gov. Gavin Newsoms revised 2023-24 budget proposal:

I am grateful that Gov. Newsoms revised budget proposal maintains critical funding for the University of California. This budget reflects our strong partnership with the Governor and his recognition of the Universitys role in maintaining the states economic competitiveness and solving Californias most urgent issues. This level of funding is particularly extraordinary given the many competing priorities the Governor must balance this year.

If supported by the state Legislature, this budget will provide funding for the urgent priorities we share, increasing California undergraduate and graduate student enrollment, expanding on-campus student resources, building additional student housing, and hiring more faculty and staff.

We are also pleased that the Governors budget includes $100 million for the California Institute for Immunology and Immunotherapy at UCLA and $2 million for the UC Riverside School of Medicine. These investments will translate into lifesaving research and patient care for many Californians.

The University of California looks forward to working with the Governor and state legislative leaders to achieve a final budget that maintains this critical funding. This state support will allow the University to continue educating the next generation of leaders, producing cutting-edge research for the benefit of our communities, and delivering high quality health care to Californians.

Link:
UC statement on Gov. Newsom's 2023-24 revised budget proposal - University of California

Immunology

Jasper Therapeutics (JSPR) Appoints Stephen J. Galli to its Board – StreetInsider.com

May 13, 2023 medical

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Dr. Stephen J. Galli, Professor of Pathology, Microbiology and Immunology, and the Mary Hewitt Loveless, M.D. Professor at Stanford Medicine, to the companys Scientific Advisory Board.

We are thrilled to welcome Dr. Galli to our Scientific Advisory Board, said Ron Martell, CEO of Jasper Therapeutics. Dr. Galli is an internationally recognized researcher who has made pioneering contributions to the field of immunology. His extensive knowledge and research on mast cells and their crucial role in both maintaining health and contributing to various diseases will be invaluable to our research and development efforts. This appointment enhances the already deep expertise resident in our Scientific Advisory Board, and we look forward to his guidance as we advance our development program for briquilimab in chronic spontaneous urticaria and other mast cell diseases.

Dr. Galli is Professor of Pathology, Microbiology and Immunology and the Mary Hewitt Loveless, M.D. Professor at Stanford Medicine. He currently is also a member of the Executive Committee of the Stanford Institute for Immunity, Transplantation and Infection. He previously was Chair of the Department of Pathology at Stanford and Co-Director of the Stanford Center for Genomics and Personalized Medicine. He leads the Galli Laboratory at Stanford Medicine, a lab focused on developing and employing innovative approaches to understanding the development and function of mast cells and basophils. Dr. Galli and his team conduct research in food allergy, asthma, atopic dermatitis and other disorders, with the goal of elucidating the role of these cells in human health and disease.

Dr. Galli earned his BA in biology from Harvard College, a BMS from Dartmouth Medical School and his M.D. from Harvard Medical School. He completed his residency and chief residency in Anatomic Pathology at Massachusetts General Hospital (MGH). After postdoctoral training with Harold F. Dvorak at MGH, Dr. Galli joined the faculty at Harvard Medical School as Assistant Professor of Pathology, becoming full professor of pathology. Before joining Stanford, he served as director of the Division of Experimental Pathology at Beth Israel Deaconess Medical Center and was member of the Harvard Medical School Committee on Immunology.

About Jasper

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at http://www.jaspertherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimabs potential, including with respect to its potential to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes as well as novel stem cell transplant conditioning regimes and Jaspers expectations regarding advancing its development program for briquilimab in chronic spontaneous urticaria and other mast cell diseases. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jaspers product candidates may not be beneficial to patients or successfully commercialized; patients willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jaspers filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022. If any of these risks materialize or Jaspers assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

John Mullaly (investors)LifeSci Advisors617-429-3548[emailprotected]

Jeet Mahal (investors)Jasper Therapeutics650-549-1403[emailprotected]

Lauren Barbiero (media)Real Chemistry646-564-2156[emailprotected]

Source: Jasper Therapeutics

More here:
Jasper Therapeutics (JSPR) Appoints Stephen J. Galli to its Board - StreetInsider.com

Immunology

DICE Therapeutics Reports First Quarter 2023 Financial Results and … – InvestorsObserver

May 13, 2023 medical

DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.

Our oral IL-17 franchise continues to advance on multiple fronts. The first psoriasis patient has been dosed in our global, dose-ranging Phase 2b clinical trial of DC-806, said Kevin Judice, Ph.D., CEO of DICE. We also look forward to topline data in healthy volunteers from our Phase 1 trial with our second oral IL-17 inhibitor, DC-853, expected in the second half of 2023. Additionally, we are excited about the progress of our earlier stage research and development (R&D) programs and continuing to utilize our DELSCAPE platform to accelerate the expansion of our pipeline to other validated targets in immunology.

Recent Highlights & Upcoming Events

First Quarter 2023 Financial Highlights

About the DICE Oral IL-17 Franchise DICE is developing orally-available, small molecule antagonists of the pro-inflammatory signaling molecule IL-17, an immune cell-derived cytokine. Blockade of this pathway has proven to be an effective therapy in a number of auto-immune diseases. The anti-IL-17 injectable biologics have been approved for the treatment of psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.

The DICE oral IL-17 franchise includes the lead therapeutic candidate, DC-806, the differentiated fast-follower candidate, DC-853, and the novel scaffold program. DICE is developing its lead therapeutic candidate, DC-806, for the treatment of psoriasis and plans to expand development to additional indications in which the marketed anti-IL-17 injectable biologics have proven to be effective. The Company is considering multiple applications for its differentiated fast-follower, DC-853, including potential development in distinct indications from DC-806, such as hidradenitis suppurativa.

About DICE Therapeutics, Inc. DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE is initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. The Companys DELSCAPE platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. DICEs lead therapeutic candidates are oral antagonists of the pro-inflammatory signaling molecule, IL-17, which is a validated drug target implicated in a variety of immunology indications. DICE is also developing oral therapeutic candidates targeting the integrin 47 for the treatment of inflammatory bowel disease.

Forward Looking Statements This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the Companys future plans and prospects, the Companys anticipated runway, any expectations regarding the safety or efficacy of DC-806 and other candidates under development, the ability of DC-806 to treat psoriasis or related indications, the planned timing of the Companys clinical trials, data results and further development of DC-806 and DC-853. In addition, when or if used in this press release, the words may, could, should, anticipate, believe, estimate, expect, intend, plan, predict and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Companys forward-looking statements due to a variety of factors, including risks and uncertainties related to the Companys ability to advance DC-806, DC-853 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the Companys therapeutic candidates, the timing and results of preclinical and clinical trials, the Companys ability to fund development activities and achieve development goals, the impact of the COVID-19 pandemic on the Companys business, its ability to protect its intellectual property and other risks and uncertainties described under the heading Risk Factors in the Companys annual report on Form 10-Q filed on May 11, 2023,and its otherSECfilings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

DICE THERAPEUTICS, INC. Condensed Consolidated Statements of Operations (unaudited) (In thousands, except share and per share amounts)

DICE THERAPEUTICS, INC. Selected Consolidated Balance Sheet Data (unaudited) (In thousands)

Contacts:

Media: Katie Engleman, 1AB katie@1abmedia.com

Investors: investors@dicetx.com

Visit link:
DICE Therapeutics Reports First Quarter 2023 Financial Results and ... - InvestorsObserver

Immunology

NYU Langone Health in the NewsFriday, May 12, 2023 – NYU Langone Health

May 13, 2023 medical

Media Highlights from Dr. Lorna Thorpes Sleep Apnea and Long-COVID Study

Obstructive Sleep Apnea Associated with Increased Risks for Long COVIDNational Institutes of Health May 11-Lorna E. Thorpe, PhD, MPH, professor, Department of Population Health

Sleep Apnea Boosts Odds for Long COVIDThis article was picked up by news websites across the country.HealthDay May 12-Hannah Mandel, senior data scientist, NYU Langone Health

Long COVID Risk Higher in People with Sleep ApneaReuters Health Rounds May 11-Hannah Mandel, senior data scientist, NYU Langone Health*Link is unavailable. Please see full test at end of report.

Obstructive Sleep Apnea Associated with Increased Risk for Long COVIDThe Clinical Services Journal May 12-Lorna E. Thorpe, PhD, MPH, professor, Department of Population Health

Obstructive Sleep Apnea Increases Risk of Long COVID in AdultsHCPLive May 11-Lorna E. Thorpe, PhD, MPH, professor, Department of Population Health

At Least 2 Cases of Drug-Resistant Ringworm Infection Found in the U.S., CDC SaysThis article was picked up by news websites across the country.NBC News May 11-Avrom S. Caplan, MD, assistant professor, the Ronald O. Perelman Department of Dermatology

Two Cases of Drug-Resistant Ringworm Detected in New York City, CDC Report FindsTODAY May 11-Avrom S. Caplan, MD, assistant professor, the Ronald O. Perelman Department of Dermatology

Cases of Drug-Resistant Fungal Ringworm Spotted in New York CityThis article was picked up by news websites across the country.HealthDay May 11-Avrom S. Caplan, MD, assistant professor, the Ronald O. Perelman Department of Dermatology-Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine

NYU Researcher Calls Attention to Lack of Health Research on Asian American CommunityNY1 Spectrum News May 11-Stella S. Yi, MPH, PhD, associate professor, Department of Population Health

RSNA Announces Screening Mammography AI Challenge ResultsImaging Technology News May 11-Linda Moy, MD, professor, Department of Radiology, Perlmutter Cancer Center

Community Connections Help Residents Overcome Challenges and Age WellNext Avenue May 11-Marc N. Gourevitch, MD, MPH, the Muriel G. and George W. Singer Professor of Population Health, chair, Department of Population Health, professor, Departments of Medicine and Psychiatry

Adding Exercise to Treatment Programs May Help Reduce Substance Use, Study ShowsHealth May 11-Thea Gallagher, PsyD, clinical assistant professor, Department of Psychiatry

Is It Safe to Take Allergy Medications Every Day?Verywell Health May 11-Purvi S. Parikh, MD, clinical assistant professor, Department of Pediatrics, Division of Pediatric Allergy & Immunology, and Department of Medicine, Division of Infectious Diseases, Allergy and Immunology

Peanut Allergy Skin Patch Shows Promise for ToddlersTODAY May 11-Natalie E. Azar, MD, clinical associate professor, Department of Medicine, Division of Rheumatology

Monkeypox: WHO Says No Longer Global Health EmergencyThis article was picked up by news websites across the country.Fox News May 11-Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine

New Recommendations Lower Age for First MammogramNY1 Spectrum News May 11-Francis Arena, MD, clinical professor, Department of Medicine, Division of Hematology and Medical Oncology, Perlmutter Cancer Center, NYU Langone Arena Oncology

Do Over-The-Counter Varicose Vein Treatments Actually Work?This story was picked up by news websites across the country.HuffPost May 12-Richard W. Schutzer, MD, clinical associate professor, Department of Surgery, chief, Division of Vascular Surgery, NYU Langone HospitalBrooklyn

Brooklyn Hospital Bringing Massage Services for Its NursesNews 12 May 11-NYU Langone HospitalBrooklyn

*Reuters Health Rounds, May 11, 2023 Long COVID Risk Higher in People with Sleep Apnea - Obstructive sleep apnea may significantly increase the risk of long COVID in adults, according to a new study. Researchers reviewed information from two National Institutes of Health databases on more than 2 million U.S. adults who tested positive for the SARS-CoV-2 virus between March 2020 and February 2022.In one database tracking 1.7 million people with a high rate of chronic health problems, those with sleep apnea had a 75% higher risk for long COVID - with symptoms such as brain fog and fatigue that can last for months after initial infection - than people without the breathing problem, researchers reported on Thursday in Sleep. In a smaller database, with roughly 300,000 adults, those with sleep apnea had a 12% higher risk for long COVID.The increased long COVID risk in people with sleep apnea persisted, but wasn't as high, after researchers accounted for other factors known to increase the risk for lingering symptoms, such as obesity, hypertension, diabetes, and hospitalization at the time of their initial COVID infection. In obstructive sleep apnea, the airway intermittently closes during sleep and breathing stops. In North America, approximately 34% of men and 17% of women are affected, according to a 2019 report in The Lancet Respiratory Medicine."People with sleep apnea who get infected with COVID should seek early treatment, pay attention to their symptoms, and keep up with their vaccinations to lower the risk of infection in the first place," study leader Hannah Mandel of NYU Langone Health in New York said in a statement.

See the original post here:
NYU Langone Health in the NewsFriday, May 12, 2023 - NYU Langone Health

Immunology

UNION therapeutics to present at 4th Annual Dermatology Drug … – InvestorsObserver

May 13, 2023 medical

HELLERUP, Denmark , May 10, 2023 /PRNewswire/ -- UNION therapeutics A/S (UNION), a privately held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. Kjller, CEO of UNION therapeutics will present at the seminar on hidradenitis suppurativa (HS) at the 4 th Annual Dermatology Drug Development Summit Europe on May 22-24, 2023 , in Berlin, Germany . Dr. Kjller will discuss the current HS landscape incl. learnings on new ways to develop better treatments across dermatology and immunology.

Dr. Kjller will also be moderating a pre-conference workshop on "Dermatological Development Strategies: Setting yourself up for success and reducing time to market" on Monday May 22, 2023 , at 1-4pm CEST .

4 th Annual Dermatology Drug Development Summit Europe

Seminar: What's next for hidradenitis suppurativa, new opportunities, new endpoints, new beginnings

Presenter: Dr. Kim D. Kjller, CEO, UNION therapeutics

Date and time: Wednesday May 24, 2023, at 1:00pm CEST .

Contacts

Morten Boesen , Chief Financial Officer, UNION therapeutics A/S +45 2381 5487 morten.boesen@uniontherapeutics.com

Sarah Toft-Jrgensen, Director of Communications and IR, UNION therapeutics A/S +45 5385 3044 stj@uniontherapeutics.com

About UNION therapeutics

UNION therapeutics is a privately held, mid- to late-stage, pharmaceutical development company advancing novel treatment options within immunology and infectious diseases, two large and fast-growing therapeutic areas. UNION is headquartered in Hellerup, Denmark , and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at http://www.uniontherapeutics.com

The following files are available for download:

View original content: https://www.prnewswire.com/news-releases/union-therapeutics-to-present-at-4th-annual-dermatology-drug-development-summit-europe-301820540.html

SOURCE UNION therapeutics

Read the rest here:
UNION therapeutics to present at 4th Annual Dermatology Drug ... - InvestorsObserver